Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Product Development, regulatory affairs chiefs, and commercial directors from endodontic device manufacturers, dental materials companies, and OEMs. Board-certified endodontists, general dentists, dental clinic procurement leads, hospital dental department heads, and dental academic institution faculty constituted demand-side sources. Primary research has confirmed the timelines of product pipelines, gathered insights on clinical adoption patterns, pricing strategies, and reimbursement dynamics, and validated market segmentation across procedure types (nonsurgical root canal, secondary root canal, apicoectomy, pulpotomy, pulpectomy), drug categories (anesthetics, painkillers, antibiotics), and device segments (crowns, endodontic instruments).
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
By Region: North America (38%), Europe (29%), Asia-Pacific (25%), Rest of World (8%)
Global market valuation was derived through revenue mapping and procedure volume analysis. The methodology included:
Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in endodontic instruments, obturation materials, and restorative devices
Product mapping across nonsurgical root canal, secondary root canal, apicoectomy, pulpotomy, pulpectomy procedures, and anesthetics, painkillers, antibiotics drug categories, plus crowns and endodontic instruments device segments
Analysis of reported and modeled annual revenues specific to root canal treatment portfolios
Coverage of manufacturers representing 70-75% of global market share in 2024
Extrapolation using bottom-up (procedure volume × ASP by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations